News & Events

Events 1

OncoSec Corporate Presentation
Events 1

CEO Letter

OncoSec Presents Interim Data of 28.5% Objective Response Rate (ORR) from Ongoing KEYNOTE-890 Study Evaluating TAVO™ in Combination with KEYTRUDA® for Heavily Pretreated, Late-Stage, Metastatic Triple Negative Breast Cancer (mTNBC) at the 2019 San Antonio Breast Cancer Symposium

December 13, 2019

OncoSec CEO Sends Letter to Fellow Shareholders

December 12, 2019

Fran’s Story

Reclaiming Independence from Melanoma

“I was headed down a one-way street with dead end.”

Watch Video

Designed to Arm the Immune System to Fight Cancer

We are investigating the potential for our lead product candidate, TAVO, through the intratumoral administration of IL-12, to stimulate systemic immune response and to become an innovative and potentially transformative therapy option for the treatment of cancer.

Clinical Pipeline

Our core technology platform continues to advance through clinical trials for various cancers

Learn More

Technology

Our plasmid DNA delivery platform is designed to boost the body’s immune system to target and attack cancer

Learn More

Partnerships

We have a track record of establishing, operating and evolving high-performance partnerships globally

Learn More
It's all about you

Visit our Patient Portal
New Approaches, New Hope

Learn More About Oncosec
“TAVO” IL-12

Fighting tumors directly.

Featured Articles

Events 1

Nature Gene Therapy

Characterization of abscopal effects of intratumoral electroporation-mediated IL-12 gene therapy READ ARTICLE

September 30, 2019
Events 1

PharmaVoice: The Intersection of Physics and Biology

Daniel O'Connor, President and CEO of OncoSec, talks about his company's efforts to develop new technologies to stimulate the body's...

September 1, 2019
Events 1

Intra Tumoral Delivery

Arming the Immune System; Turning Cold Tumors Hot Read Article

September 1, 2019